Comparative Real‐World Safety Profiles of Fibroblast Growth Factor Receptor Inhibitors: A Pharmacovigilance Study
Asia-Pacific Journal of Clinical Oncology · 22.06.2026
DOI: 10.1111/ajco.70133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 22.06.2026. Verfasst von Seda Jeral Evinç und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Istanbul University-Cerrahpaşa, Department of Medical Oncology, Istanbul, Turkey. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objectives
This study aimed to compare the real‐world safety profiles of approved fibroblast growth factor receptor (FGFR) inhibitors and to identify drug‐specific adverse event patterns using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Methods
A retrospective pharmacovigilance analysis was conducted using FAERS reports submitted between January 1, 2014, and October 31, 2025. Adverse event reports involving erdafitinib, pemigatinib, futibatinib, and infigratinib were included when an FGFR inhibitor was listed as the primary suspect drug. Adverse events were coded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 28.0 and categorized by System Organ Class. Disproportionality analyses were performed using reporting odds ratios (RORs) with 95% confidence intervals (CIs).
Results
A total of 2081 FGFR inhibitor‐related adverse event reports were identified. Erdafitinib accounted for the largest proportion of reports (53.8%), followed by pemigatinib (34.8%), futibatinib (8.2%), and infigratinib (3.2%). Overall, 69.8% of reported events were classified as serious. Infigratinib showed a markedly increased reporting likelihood for blurred vision (ROR 8.92; 95% CI: 3.73–21.36) and oral mucosal toxicity (ROR 3.38; 95% CI: 1.80–6.34). Hyperphosphatemia was most strongly associated with futibatinib (ROR 3.11; 95% CI: 1.93–5.01), whereas erdafitinib demonstrated a reduced reporting likelihood for this event (ROR 0.43; 95% CI: 0.29–0.63). Ocular adverse events, including dry eye, exhibited variable reporting patterns across agents.
Conclusion
FGFR inhibitors demonstrated differences in adverse event reporting patterns rather than a uniform class effect, although pharmacovigilance data do not allow estimation of true incidence, risk, or causal relationships.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Istanbul University-Cerrahpaşa, Department of Medical Oncology, Istanbul, Turkey.
- Department of Medical Oncology, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Istanbul, Turkey.
Zitieren
APA
Evinç, S. J., Akmercan, Ç. E., Birsin, Z., Cebeci, S., Çerme, E., Aliyev, V., Abbasov, H., Çiçek, E., Atak, S., Demirci, N. S., Papila, Ç., & Alan, Ö. (2026). Comparative Real‐World Safety Profiles of Fibroblast Growth Factor Receptor Inhibitors: A Pharmacovigilance Study. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.70133
Vancouver
Evinç SJ, Akmercan ÇE, Birsin Z, Cebeci S, Çerme E, Aliyev V, et al. Comparative Real‐World Safety Profiles of Fibroblast Growth Factor Receptor Inhibitors: A Pharmacovigilance Study. Asia-Pacific Journal of Clinical Oncology. 2026. doi:10.1111/ajco.70133
BibTeX
@article{Evin2026,
author = {Evinç, Seda Jeral and Akmercan, Çağla Eyüpler and Birsin, Zeliha and Cebeci, Selin and Çerme, Emir and Aliyev, Vali and Abbasov, Hamza and Çiçek, Ebru and Atak, Süheyla and Demirci, Nebi Serkan and Papila, Çiğdem and Alan, Özkan},
title = {Comparative Real‐World Safety Profiles of Fibroblast Growth Factor Receptor Inhibitors: A Pharmacovigilance Study},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
doi = {10.1111/ajco.70133}
}
EUVIMED